Jake is an associate at Ciresi Conlin. Before joining the firm, he was a judicial law clerk for the Honorable David R. Stras of the United States Court of Appeals for the Eighth Circuit and a litigator at a large New York City law firm. His experience spans commercial, intellectual property, and antitrust litigation. He has represented companies in a wide variety of sectors, from pharmaceuticals and biotechnology to nonprofit organizations and from consumer goods to heavy manufacturing. He has also maintained an active pro bono practice representing indigent individuals and community organizations, with an emphasis on protecting the rights of children and working families.
Jake is a graduate of Yale Law School where he was a student director of the Advocacy for Children & Youth Clinic, a member of the Educational Opportunity and Juvenile Justice Clinic, and co-director of the Temporary Restraining Order Project. He received his undergraduate degree in mathematics, magna cum laude, from Williams College.
Represented a foreign manufacturing company in a high-stakes, complex commercial dispute with its joint venture partner, ending in the grant of summary judgment to the client on the central issue of liability.
Successfully represented a major pharmaceutical company in an ANDA action involving challenges to patents covering a combination drug therapy and processes for its manufacture, leading to a favorable settlement.
Represented an online content provider in data piracy claims arising from unauthorized access to its proprietary database, leading to a series of confidential settlements.
Successfully defended a major pharmaceutical company against tying and monopolization claims, resulting in grant of a motion to dismiss.
Defended a leading consumer goods company in a nationwide class action litigation involving allegations of anticompetitive pricing.
*Case results were achieved while Jake was at a former firm.
“PTAB and Bar Prepare for Aftermath of Supreme Court’s SAS Decision,” IP Litigator, Volume 24, Number 4 (July/August 2018)
“U.S., European Biosimilar Approval Activity in 2017,” Bloomberg BNA Life Sciences Law & Industry Report (February 2018)
“Update on Biosimilar Approvals and Pending Applications in Europe and the U.S.,” Bloomberg BNA Life Sciences Law & Industry Report (June 2017)